SPRY
ARS Pharmaceuticals Inc.
$7.59
+$0.86(+12.78%)
29
Overall
50
Value
9
Tech
--
Quality
Market Cap
$888.65M
Volume
3.90M
52W Range
$6.73 - $18.90
Target Price
$27.83
Company Overview
| Mkt Cap | $888.65M | Price | $7.59 |
| Volume | 3.90M | Change | +12.78% |
| P/E Ratio | 111.1 | Open | $6.69 |
| Revenue | $89.1M | Prev Close | $6.73 |
| Net Income | $8.0M | 52W Range | $6.73 - $18.90 |
| Div Yield | N/A | Target | $27.83 |
| Overall | 29 | Value | 50 |
| Quality | -- | Technical | 9 |
No chart data available
About ARS Pharmaceuticals Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Latest News
ARS Pharmaceuticals (SPRY) Gets a Buy from Oppenheimer
TipRanks Auto-Generated Intelligence Newsdesk•12 days ago
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SPRY | $7.59 | +12.8% | 3.90M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ARS Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW